TOPLINE
In this interview with Mark Bishofsky, Pfizer whistleblower Brook Jackson describes the egregious errors she saw working for a Pfizer subcontractor during the pharma giant’s COVID-19 “vaccine” clinical trial. Jackson, whose False Claim Act case against Pfizer brought to light the fact that the corporation’s clinical trial was not required to follow Good Clinical Practices (GCP) nor FDA regulations, describes her fearing for patients’ safety, “a lack of informed consent,” and the fabrication and falsification of data, amongst other major issues.
In this interview with “freedom fighter” Mark Bishofsky, Pfizer whistleblower Brook Jackson describes what she saw as a regional director for Ventavia Research Group, a Pfizer subcontractor, during the pharma giant’s COVID-19 “vaccine” clinical trial. Jackson, whose False Claim Act case against Pfizer brought to light the fact that the fraudulent clinical trial was not required to follow Good Clinical Practices (GCP) nor FDA regulations, describes her fearing for patients’ safety, “a lack of informed consent,” and the fabrication and falsification of data, amongst other egregious problems.
“I didn’t sleep that much during those 18 days because of everything that I was seeing,” Jackson says of the 18 days she spent working as a regional director at Pfizer clinical-trial sites. “It was, and I’ve said this before… I’ve never seen a clinical trial run in a way that actually made me fearful for the patients’ safety, and this one did.”
Jackson, who was a regional director for two out of three clinical-trial sites in the Dallas–Fort Worth area, as well as Houston, highlights myriad issues with the way the trial was run. (Issues also outlined in a letter in the British Medical Journal, which can be read via the post embedded immediately below.)
“From the day I walked in, the first thing that I saw, was a lack of informed consent,” Jackson says. She adds, “There is a true lack of informed consent when any patient, any adolescent, any baby is given this injection because people are not fully informed of what they’re putting into their bodies. They weren’t then and they’re certainly not now.”
Jackson adds “That, per Pfizer’s own protocol, should’ve immediately stopped us from seeing any more patients until we were able to speak with Pfizer.”
Jackson also notes there was “Mixing up of specimens from one patient to the next.” The injections were also not stored “at the appropriate temperature.” (Jackson has brought up similar issues in other interviews before, some of which you can watch via the post embedded immediately below.)
Ventavia employees were “not collecting [records of]… serious adverse events,” Jackson says. She adds they were also “Not making sure that patients were completing their diaries appropriately. These devices that we sent home with them after they were injected to monitor their symptoms.”
“I literally could go on and on and on about the problems. The point is in 20 years I have never seen a clinical trial run this quickly, this sloppily… and a lot of it was just sloppy research,” Jackson adds.
Feature image: NAVY MEDICINE
Related News
